In this article

本文中

LLY

礼来公司

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025.

礼来公司董事长兼首席执行官戴夫·里克斯于2025年9月23日在美国德克萨斯州休斯顿举行的新闻发布会上发表讲话。

Antranik Tavitian | Reuters

安特拉尼克·塔维蒂安 | 路透社

Eli Lilly

礼来公司

on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs.

周五表示，将投资超过 35 亿美元，在宾夕法尼亚州利哈伊谷建造一家生产工厂，这将有助于生产其下一代减肥药物。

That includes a closely watched experimental drug called retatrutide, which has

其中包括一种备受关注的实验药物，称为雷塔鲁肽，这种药物

shown the highest weight loss seen to date

显示出迄今为止最高的体重减轻

for any treatment in a late-stage trial.

对于任何处于后期试验阶段的治疗。

It is the fourth facility in a string of new planned U.S. investments by the pharmaceutical giant. Lilly announced in February 2025 that it

这是这家制药巨头计划在美国进行的一系列新投资中的第四家设施。礼来公司于2025年2月宣布

would spend at least $27 billion

将至少花费270亿美元

to build new domestic manufacturing facilities, adding to $23 billion in previous investments since 2020.

建设新的国内制造设施，自2020年以来已追加230亿美元的前期投资。

On Thursday, President

周四，总统

Donald Trump

唐纳德·特朗普

said Lilly CEO Dave Ricks has told him the drugmaker aims to

礼来公司首席执行官戴夫·里克斯表示，他被告知该制药商的目标是

build six plants in the U.S.

在美国建造六家工厂

But Lilly has not confirmed those plans.

但是礼来公司尚未确认这些计划。

The company on Friday said it expects construction of the Pennsylvania plant to start this year and for the site to be operational in 2031.

公司周五表示，预计宾夕法尼亚州工厂的建设将于今年开始，并于2031年投入运营。

That added production capacity for upcoming weight loss treatments is crucial. Retatrutide is viewed as a key pillar of Lilly's long-term obesity strategy after its popular injection Zepbound and upcoming obesity pill.

这种为即将到来的减肥治疗增加的生产能力至关重要。在礼来公司受欢迎的注射剂Zepbound和即将推出的减肥药之后，Retatrutide被视为礼来公司长期肥胖战略的关键支柱。

Some health experts say retatrutide, which works by targeting three gut hormones rather than one or two, can reach patients with severe obesity who would benefit from even more weight loss than what existing injections can offer. Lilly plans to release data from seven other phase three trials on the drug this year.

一些健康专家表示，retatrutide 通过针对三种肠道激素而不是一两种起作用，可以帮助那些现有注射药物无法满足需求的重度肥胖患者实现更多的减重效果。礼来公司计划在今年发布该药物另外七项三期试验的数据。

.

。

The company and its chief rival,

公司及其主要竞争对手，

Novo Nordisk

诺和诺德

, have invested heavily in boosting production capacity after previously facing supply shortages for their existing weekly injections in the U.S.

此前在美国市场面临现有周注射剂供应短缺的问题，现已大力投资提高生产能力。

Preparing enough supply of upcoming drugs is also central to Lilly's efforts to maintain its dominance in the booming GLP-1 market. The company secured the majority share in the space last year for the first time, overtaking Novo.

为即将到来的药物准备足够的供应也是礼来公司维持其在蓬勃发展的GLP-1市场主导地位的核心努力。该公司去年首次在这个领域获得了大部分市场份额，超过了诺和诺德。

But the Danish drugmaker is hoping to close the gap with the launch of the

但这家丹麦制药商希望通过推出

first-ever GLP-1 pill

首个GLP-1药丸

for obesity this month, which has already

对于肥胖症，这个月已经有

racked up thousands of U.S. prescriptions

累计了数千张美国处方

. Lilly has its own pill, orforglipron, that could win approval and launch later this year.

礼来公司有自己的药物orforglipron，可能在今年晚些时候获得批准并上市。

Drugmakers have been scrambling to boost their production in the U.S. after threats by President

在总统威胁之后，制药商一直在努力提高他们在美国的产量

Donald Trump

唐纳德·特朗普

to impose tariffs on pharmaceuticals imported into the U.S. But concerns about those potential tariffs have eased following voluntary drug pricing deals with Trump in recent months that exempt companies – including both Lilly and Novo – from the levies for three years.

对进口到美国的药品征收关税。但在过去几个月中，随着特朗普达成自愿性的药品定价协议，这些公司（包括礼来和诺和）获得三年的关税豁免，因此对潜在关税的担忧有所缓解。

Eli Lilly said the Pennsylvania site will bring 850 jobs to the area, including engineers, scientists, operations personnel and lab technicians, as well as 2,000 construction jobs.

礼来公司表示，宾夕法尼亚州的工厂将为该地区带来850个就业岗位，包括工程师、科学家、运营人员和实验室技术员，以及2000个建筑工作岗位。